The FDA has granted final approval to the first short-acting follow-on insulin product, Sanofi’s Admelog (insulin lispro injection). Admelog is indicated to improve insulin control in blood sugar levels in adults and children aged 3 years and older who have type 1 diabetes and in adults who have type 2 diabetes.
The FDA has granted final approval to the first short-acting follow-on insulin product, Sanofi’s Admelog (insulin lispro injection). Admelog is indicated to improve insulin control in blood sugar levels in adults and children aged 3 years and older who have type 1 diabetes and in adults who have type 2 diabetes.
"Admelog will offer a more affordable option for those who require control of their blood sugar levels at mealtime," said Stefan Oelrich, executive vice president and head, global diabetes and cardiovascular, Sanofi, in a statement. "The approval of Admelog is an important milestone for Sanofi in our mission to serve patients living with chronic diseases such as diabetes."
FDA Commissioner Scott Gottlieb, MD, added, “One of my key policy efforts is increasing competition in the market for prescription drugs and helping facilitate the entry of lower-cost alternatives. This is particularly important for drugs like insulin that are taken by millions of Americans every day for a patient’s lifetime to manage a chronic disease. In the coming months, we’ll be taking additional policy steps to help to make sure patients continue to benefit from improved access to lower cost, safe and effective alternatives to brand name drugs approved through the agency’s abbreviated pathways.”
Final approval of the drug follows the FDA’s tentative approval, granted in September 2017. The agency did not issue its final approval until the resolution of patent disputes with the reference Humalog’s sponsor, Eli Lilly.
Admelog’s tentative approval was based on its similarity to the innovator Humalog. However, because the FDA treats innovator insulins as drugs, rather than as biologic products, treatments such as Admelog are regulated as “follow-ons,” not as biosimilars. The European Union addresses these products differently; Admelog is approved by the European Medicines Agency as a biosimilar insulin product, and the drug is marketed in the European Union under the proprietary name Insulin lispro Sanofi.
However, as Scott Lassman, JD, partner at Goodwin’s technology and life sciences group, explained to The Center for Biosimilars® in a recent interview, “Very soon, in 2020, all those products, like insulin, which are now regulated as drugs and get approved through [New Drug Applications] and 505(b)(2) applications, they’re all going to be transitioned to biologics and they’re going to have to submit [Biologics License Applications]. So, this [follow-on] issue won’t exist for much longer.”
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.